Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients with melanoma and the unique genetic mutations that may accompany the disease, according to data ...
Nov 15, 2011
0
0
In a phase three clinical trial, a drug called sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment, a significant increase in progression-free survival compared ...
Dec 19, 2018
0
13
New treatment options for people with advanced or unresectable hepatocellular carcinoma (HCC) may now be a step closer after three research groups presented safety and efficacy data at the Digital International Liver Congress ...
Aug 28, 2020
0
2
Scientists at Virginia Commonwealth University Massey Cancer Center may be one step closer to developing a new therapy for acute myeloid leukemia (AML) after discovering that the targeted agents obatoclax and sorafenib kill ...
May 22, 2012
0
0
The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research ...
May 2, 2012
0
0
A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. ...
Jun 22, 2016
0
2
A study led by Xiujun Cai (Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine) screened the whole genome of hepatocellular carcinoma cells (HepG2) through CRISPR / cas9 system ...
Apr 19, 2022
0
2
(HealthDay)—For patients with advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival (OS) is dependent on patients' hepatitis status, according to a meta-analysis published online Jan. ...
Jan 9, 2017
0
0
(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.
Nov 24, 2013
0
0
Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.
Nov 6, 2012
0
0
